Allergy Therapeutics PLC

Other News To Note.
BIOWORLD Today; 11/4/2009; 1824 words; ...subsidiary of Shire Pharmaceuticals Group plc, of Andover, UK, which contributed...million grant from the National Institute of Allergy and Infectious Diseases, part of the...the maximum offering price. o Esperion Therapeutics Inc., of Ann Arbor, Mich., began...

Coley Acquires TLR7 And TLR8 Programs From 3M For $20M.
BIOWORLD Today; 11/3/2009; 1279 words; ...have utility in asthma, allergy, viral diseases and...saying only that TLR therapeutics are applicable across...Phase I TLR9 asthma/allergy program. Additionally, GlaxoSmithKline plc, Novartis AG, Merck...deal with AstraZeneca plc for the development of...

Coley's VaxImmune Adjuvant Subject Of $37M Merck Deal.
BIOWORLD Today; 11/3/2009; 1142 words; ...companies such as GlaxoSmithKline plc and Novartis AG. "We really...London-based AstraZeneca plc agreed to pay up to $136 million...internal pipeline involves therapeutics rather than vaccines, Bratzler...targeted compounds against allergy, allergic rhinitis and chronic...

Coley's Anti-Terrorism TLRs Get Another $16.9M Contract.
BIOWORLD Today; 11/3/2009; 1141 words; ...contract from the National Institute of Allergy and Infectious Diseases (one of the NIH...pathogens. Coley already has shown that its therapeutics targeting TLR9 can stimulate protective...arrangements are in place with GlaxoSmithKline plc, of London, and Emeryville, Calif...

Acambis: Just One Part Of New Vaccine Development.
BIOWORLD Today; 11/3/2009; 1026 words; ...On the same day Acambis plc announced that it had suspended...in Biodefense Vaccines and Therapeutics symposium in Washington...the National Institute of Allergy and Infectious Diseases in...agents also can include new therapeutics to treat the disease and in...